This observational study is looking at whether a problem with a protein called CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) might be a cause of chronic rhinosinusitis (CRS). Researchers believe that issues with CFTR could create an environment in your nose that makes it harder for mucus to clear. They will measure something called Nasal Potential Difference (NPD), which is a way to check how well CFTR is working. This measurement involves perfusing (gently washing) your nasal passages with different solutions, including Ringer's solution, amiloride, and isoproterenol, while monitoring electrical signals. The study aims to see if there's a measurable difference in CFTR function after one year. You can join if you are 18 or older, have CRS, and are otherwise healthy enough to participate safely. The study is currently unclear on its recruitment status and plans to enroll 20 participants.

Study design

This is an observational study with an unclear status, planning to enroll 20 participants. It will measure CFTR function using a 4-step protocol.

What's involved

You will undergo Nasal Potential Difference (NPD) measurements, which involve perfusing your nasal cavities with different solutions. The potential difference will be monitored in your nasal epithelium.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, a measurable difference in CFTR function, will be assessed at one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.